New Developments in Health: Drug Approvals and Market Reactions

The FDA has approved an injectable version of the cancer drug Opdivo by Bristol Myers Squibb. Meanwhile, Axsome's Alzheimer's drug AXS-05 had mixed results in trials. Roche's CEO confirmed no job cuts despite challenges in developing new drugs. Stock market reactions were observed for these updates.

The FDA has given the green light to an injectable form of Bristol Myers Squibb's cancer medication, Opdivo. Known as a PD-1 inhibitor, Opdivo boosts the immune system to better combat cancer by removing its natural restraints.

In other news, Axsome Therapeutics revealed mixed results from trials of its Alzheimer's treatment, AXS-05. One major trial showed success, while another did not meet its main objectives, causing the company's shares to dip by 12% in premarket trading.

Meanwhile, Roche's CEO, Thomas Schinecker, reported a stable business environment with no planned job cuts, despite recent setbacks in drug development. The company's shares have experienced a decline since reaching peaks in 2022.